Chief Policy Officer Daniel Pabon departs Medicine Man Technologies; receives $250K severance

Medicine Man Technologies, Inc.

Daniel Pabon terminated as Chief Policy and Regulatory Affairs Officer effective April 30, 2025.
Severance: $250,000 cash (12 months base salary) plus 12 months COBRA subsidy.
Equity vesting accelerated for options vesting May 3, 2025; exercise period extended to expiration.
Departure part of strategic restructuring to consolidate roles and eliminate redundancies.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Daniel Pabon

Chief Policy and Regulatory Affairs Officer

Medicine Man Technologies, Inc.

Effective: 2025-04-30
Filed: May 6, 2025, 7:59 PM ET

On May 2, 2025, Medicine Man Technologies, Inc. (the “Company”) and Daniel Pabon, the Company’s Chief Policy and Regulatory Affairs Officer, entered into a Separation Agreement and Release (“Separation Agreement”), pursuant to which Mr. Pabon’s employment with the Company terminated effective April 30, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Pabon was terminated as Chief Policy and Regulatory Affairs Officer at Medicine Man Technologies, Inc..

Action: terminated
Role: Chief Policy and Regulatory Affairs Officer

Exact text from the filing

On May 2, 2025, Medicine Man Technologies, Inc. (the “Company”) and Daniel Pabon, the Company’s Chief Policy and Regulatory Affairs Officer, entered into a Separation Agreement and Release (“Separation Agreement”), pursuant to which Mr. Pabon’s employment with the Company terminated effective April 30, 2025.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-25-045029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.